Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.

Authors

Mainak Banerjee, Ajitesh Roy, Vivek Mohan Sharma, Abhishek Das

Published in

Obesity (Silver Spring, Md.). Aug 19, 2026. Epub Aug 19, 2026.

Abstract

This study aimed to compare the effectiveness of tirzepatide versus injectable semaglutide in preventing major adverse liver outcomes (MALO) among adults with overweight or obesity and type 2 diabetes.
This retrospective target trial emulation utilized the TriNetX global network to analyze new users of tirzepatide and semaglutide. The primary outcome was time-to-first MALO (a composite of cirrhosis, decompensated events, and hepatocellular carcinoma). Propensity score matching balanced baseline covariates.
Over a median follow-up of ~17 months, no significant difference in MALO risk was observed between tirzepatide and semaglutide initiators (estimated incidence rate [IR] 4.05 vs. 4.04 per 1000 person-years [PY]; hazard ratio [HR] 1.04, 95% CI 0.88-1.23). This comparable risk profile was maintained across sensitivity analyses, including people with MASLD (IR 9.97 vs. 10.03 per 1000 PY; HR 1.03, 95% CI: 0.75-1.42) and "as treated" analysis (HR 0.98, 95% CI: 0.80-1.21). Tirzepatide achieved greater BMI reduction (mean difference ~1.1 kg/m², p < 0.001). Internal validation confirmed both agents significantly outperformed sitagliptin.
In this high-risk population with type 2 diabetes, tirzepatide and injectable semaglutide offered comparable effectiveness in mitigating liver disease progression and MALO in the short- to medium-term follow-up.

PMID:
42618523
Bibliographic data and abstract were imported from PubMed on 20 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.